Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2022-12-12 00:00:00 ET · period of report 2022-12-08 · accession 0001883850-22-000107 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-12-12 | 2022-12-08 | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $381.92 | +3,000 | 31.7K | +10% | +$1.15M |
| DM | 2022-12-12 | 2022-12-08+ | REGN | Landry Robert E | EVP Fin CFO | F - Tax | $765.81 | -2,753 | 29.5K | -9% | -$2.11M |
| D | 2022-12-12 | 2022-12-08 | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $0.00 | -3,000 | 3,800 | -44% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-08 | M | A | 3,000 | $381.92 | 31,744 | D | — | — | |
| 2 | Common | Common Stock | 2022-12-09 | F | D | 492 | $753.28 | 28,991 | D | — | — | |
| 3 | Common | Common Stock | 2022-12-08 | F | D | 2,261 | $768.54 | 29,483 | D | — | — | |
| 4 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-12-08 | M | D | 3,000 | $0.00 | 3,800 | D | $381.92 · — to 2026-12-16 | 3,000 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |